NanoScrips is developing novel, patent pending prodrugs and nanoparticles which significantly enhance the safety and efficacy of respective drugs. This is achieved by covalent binding of active ingredient to polymers via ester links. The drugs are released in the body by the action of esterases over an extended period of time. The current pipeline of candidates are for glaucoma, retinal neurodegeneration, radiation sensitization of tumor (ex: Glioblastoma/Brain cancer), NASH/Liver fibrosis, Ulcerative colitis, Epilepsy and Alzheimer's. The company has one NIH funded grant for testing its efficacy in retinal disorder. NanoScrips has research agreements with the universities and National Institutes.
Company Details
- Employees
- 1
- Address
- Dallas-Fort Worth Metroplex, Texas, Us
- Industry
- Nanotechnology Research
- NAICS
-
Research and Development in Nanotechnology
- Website
- http://www.nanoscrips.com
- HQ
- Dallas-Fort Worth Metroplex, Texas
Nanoscrips Questions
Nanoscrips's website is http://www.nanoscrips.com
Nanoscrips's LinkedIn profile is https://www.linkedin.com/company/nanoscrips
Nanoscrips has
1 employees.
View email and phone details for 1
employees at Nanoscrips.
Nanoscrips's industry is
Nanotechnology Research
Nanoscrips's categories are Nanotechnology Research
